Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Rad Laboratories (BIO)

Bio-Rad Q3 GAAP net income $458.6 million on investment gain; operating loss

Mixed Impact 3 of 5 earnings

Bio-Rad reported third-quarter 2026 net sales of $656.4 million, up 0.5% from a year earlier, and GAAP net income of $458.6 million, compared with a loss of $341.9 million in the prior-year quarter. The GAAP net income reflects a $588.2 million gain from the change in fair market value of its equity securities, while GAAP operating results were a loss of $49.7 million, including restructuring and impairment charges. The company kept its full-year 2026 outlook unchanged.

Key points

  • Net sales were $656.4 million, up 0.5%; currency-neutral sales rose 0.7%, led by Clinical Diagnostics.
  • GAAP net income was $458.6 million, or $17.02 per diluted share, versus a loss of $341.9 million, or $12.70 per share, a year earlier.
  • GAAP operating loss was $49.7 million, including $77.2 million of restructuring charges and a $49.8 million impairment of purchased intangibles.
  • Non-GAAP diluted income per share was $2.65, up from $2.26; full-year outlook was reaffirmed.

The filing

CompanyBio-Rad Laboratories (BIO)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:16 PM ET
Accession number0000012208-26-000057

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.